Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
AbbVie
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07365241CT.gov A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07141771CT.gov An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | — | Not Yet Recruiting | — | — | — |
NCT07189455CT.gov Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07218146CT.gov A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | — | Recruiting | — | — | — |
NCT07145333CT.gov Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | — | Active Not Recruiting | — | — | — |
NCT07076095CT.gov A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07106528CT.gov Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06954246CT.gov A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06801834CT.gov Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06612151CT.gov A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
Show 47 more trialsShow fewer
NCT06616532CT.gov PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06581380CT.gov JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06496048CT.gov Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | — | Recruiting | — | — | — |
NCT06500026CT.gov A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | — | Active Not Recruiting | — | — | — |
NCT06449209CT.gov Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT06498479CT.gov ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06203210CT.gov A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06128837CT.gov Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05990738CT.gov DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT05874401CT.gov Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | — | Recruiting | — | — | — |
NCT05740566CT.gov Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05800587CT.gov Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | — | Recruiting | — | — | — |
NCT05353439CT.gov Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05153239CT.gov Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | — | Completed | — | — | — |
NCT04514497CT.gov Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04902885CT.gov Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT04768296CT.gov Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | — | Completed | — | — | — |
NCT03896503CT.gov Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | — | Active Not Recruiting | — | — | — |
NCT04073550CT.gov Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04022876CT.gov A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | — | Terminated | — | — | — |
NCT03554473CT.gov M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | — | Completed | — | — | — |
NCT03088813CT.gov Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03098030CT.gov Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02963090CT.gov Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03061812CT.gov Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) | — | Completed | — | — | — |
NCT03059667CT.gov Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02980809CT.gov Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03227016CT.gov Study in Patients With SCLC of Veliparib in Combination With Topotecan | — | Unknown | — | — | — |
NCT02566993CT.gov Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT02649673CT.gov LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | — | Terminated | — | — | — |
NCT02514447CT.gov Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | — | Completed | — | — | — |
NCT02487095CT.gov Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | — | Completed | — | — | — |
NCT02200757CT.gov Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01904253CT.gov A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy | — | Terminated | — | — | — |
NCT01803269CT.gov Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01533181CT.gov Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01417806CT.gov Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00997061CT.gov SCOT Registry: Small Cell Lung Cancer Treatment and Outcome | — | Completed | — | — | — |
NCT00828139CT.gov S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00697476CT.gov Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC | — | Terminated | — | — | — |
NCT00765973CT.gov Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT00698516CT.gov Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00521144CT.gov Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | — | Completed | — | — | — |
NCT00397293CT.gov Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00098956CT.gov 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00057837CT.gov Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00252889CT.gov Doxil Topotecan Doublet Cancer Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | AbbVie | Approved | BB · 70 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nogitecan in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nogitecan-small-cell-lung-carcinoma-9301
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →